Skip to main content
. Author manuscript; available in PMC: 2014 Nov 5.
Published in final edited form as: Cancer Res. 2009 Apr 21;69(9):3910–3917. doi: 10.1158/0008-5472.CAN-08-0034

Figure 2.

Figure 2

Inhibition of cell line proliferation by APcK110. A) Dose-dependent antiproliferative effect of APcK110, imatinib, and dasatinib on OCI/AML3 cells. Using the MTT assay we demonstrate that APcK110 is a more potent inhibitor than imatinib and dasatinib. B) Dose-dependent antiproliferative effect of APcK110, cytarabine, and APcK110 plus cytarabine on OCI/AML3 cells. APcK110 is an at least equally potent inhibitor of AML cell proliferation as is cytarabine. C) Comparison of antiproliferative effect in wild-type versus mutant KIT –expressing BaF3 cells. We demonstrate preferential inhibition of KIT supported by the fact that incubation of mutant KIT-expressing BaF3 cells with IL-3 was not able to reverse the inhibition.